Seattle Genetics, Inc. $600 Million Equity Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Solid Biosciences Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…
ConforMIS, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 13,333,333 shares of common stock of ConforMis,…
Five Prime Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The…
Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of…
Agios Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of…
BeiGene, Ltd. $800 Million Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public offering by BeiGene, Ltd. of American depositary shares. The ADSs are…
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by Hologic, Inc. of $600 million aggregate principal amount of its 4…
Denali Therapeutics Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…